DLBCL - Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma, Large-cell Lymphoma, Lymphoma, Lymphoma, B-Cell, Mediastinal B-Cell Diffuse Large Cell Lymphoma
Conditions
Keywords
oncologist, hemotologic oncologist, lymphoma, large cell lymphoma, large b-cell lymphoma, DLBCL, Diffuse Large B Cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma, Hematolo-GIST, 23-164, Memorial Sloan Kettering Cancer Center
Brief summary
The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.
Interventions
BEHAVIORALParticipants Appointment
Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.
BEHAVIORALHematolo-GIST Training
Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Providers * Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma) Patients * Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, treating provider will be defined as any provider who provides care related to the patient's lymphoma diagnosis) * Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma * Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT) * Self-identify as Black and/or White * Per medical record, 18 years of age or older * Per self-report, fluent in English\*\* * Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study: 1. How well do you speak English? (must respond very well or well when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused) 2. What is your preferred language for healthcare? (must respond English)
Exclusion criteria
Providers * Per self-report, planning to leave the cancer center in the next 12 months Patients * Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11 * Per research staff judgment and/or self-report, too ill or weak to complete study procedures * Per medical record or self-report, receiving hospice care at the time of enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of the Hematolo-GIST intervention among hematologists and participants | Up to 1 year | Feasbility is defined as ≥70% of screened eligible hematologists and participants enrolling in the study and ≥80% of hematologists learning the approach |
Countries
United States
Contacts
Primary ContactKelly McConnell, PhD
Backup ContactRevecca Saracino, PhD
Outcome results
None listed